3D Printing for Cardiovascular System (Premium)
The cardiovascular system indisputably dictates the fitness level and longevity of any individual. It is also one of the top killers and debilitating conditions of modern human beings no matter where you live. “Heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States. One person dies every 36 seconds in the United States from cardiovascular disease. About 659,000 people in the United States die from heart disease each year—that’s 1 in every 4 deaths. Heart disease costs the United States about $363 billion each year from 2016 to 2017. This includes the cost of health care services, medicines, and lost productivity due to death.” [https://www.cdc.gov/heartdisease/facts.htm] But heart disease has many causes, one of which includes iatrogenic causes, a result of modern medicine. Cardiotoxicity is one of the major side effects of many cancer drugs, for example. Can 3D Bioprinting rejuvenate our hearts? To answer this question, we have invited one of the most comprehensive world-class experts from academia, industry, startup world to engage with the audiences on the possibilities of this emerging technology in solving a critical problem, topic including and not limited to bioprinting “mini-hearts”, “heart components”, “cardiac repair patch”, among others.
Vahid Serpooshan did his BSc and MSc in Materials Science and Engineering at Sharif University (Tehran, Iran, 1998-2003) and his Ph.D. in biomaterials and tissue engineering at McGill University (Montreal, Canada, 2007-2011). His Ph.D. thesis research focused on the design and optimization of scaffolding biomaterials for bone tissue engineering applications. Following his Ph.D., Dr. Serpooshan worked for 7 years at Stanford University School of Medicine as Postdoctoral Fellow (Pediatric Cardiology) and Instructor (Stanford Cardiovascular Institute). At Stanford, Dr. Serpooshan’s training and research were mainly centered on developing a new generation of engineered cardiac patch devices to repair damaged heart tissue following myocardial infarction (heart attack). The engineered patch was successfully tested in mouse and pig models and is now in preparation for clinical trials. He also worked on enabling technologies for human-machine hybrid cardiac tissue, using 3D bioprinting to assemble complex arrays of interfaces between synthetic and biological materials. In 2018, Dr. Vahid Serpooshan joined Emory University and Georgia Institute of Tech as Assistant Professor of Biomedical Engineering and Pediatrics, where his multidisciplinary team is now working on a variety of 3D bioprinting-based tissue engineering and disease modeling projects.
Asaf is a pediatrician with years of experience in the biotechnology industry. For the last 3 years, Asaf is the CEO of Matricelf, an Israeli publicly-traded company in the area of tissue engineering and regenerative medicine.
Dr Carmine Gentile, PharmD/Ph.D., FAHA, received his BSc/MSc (Pharmaceutical Chemistry and Technologies) and PharmD at the University of Pisa, Italy, and his Ph.D. in Biomedical Sciences (Cardiovascular) at the Medical University of South Carolina, Charleston, SC, USA, funded by a prestigious American Heart Association Fellowship. Since 2013, Dr. Gentile has worked in Australia at the Heart Research Institute, the University of Sydney, and now at UTS, supported by several awards and grants, working within a multidisciplinary team with scientists, industry partners, and clinicians to quickly translate his findings from bench to bedside. He currently leads the Cardiovascular Regeneration Group (www.gentilelab.com), working on 3D bioprinting and stem cell technologies for cardiovascular tissue applications both at the Kolling Institute/University of Sydney and UTS. He is a Senior Lecturer (Honorary) within the Sydney Medical School (Northern) at the University of Sydney and a Senior Lecturer (Faculty) within the School of Biomedical Engineering (Faculty of Engineering and IT) at the University of Technology Sydney.
Dr. Gentile is an internationally recognized expert in the field of 3D bioprinting and stem cell technologies and his more recent studies focus on novel molecular and cellular approaches to treat cardiovascular disease, including myocardial infarction and heart failure. These studies are based on the use of vascularized cardiac spheroids or “mini-hearts” he developed as “bio-inks” for human heart tissues. In 2016, he was invited as Visiting Research Fellow at Harvard Medical School, where he worked towards novel in-vitro models using mini-hearts to study human heart physiology.
Dr. Adam Feinberg is Co-Founder and CTO of FluidForm Inc, a start-up company commercializing FRESH 3D bioprinting technology, and a Professor at Carnegie Mellon University in the departments of Biomedical Engineering and Materials Science & Engineering. He earned his BS in Materials Science & Engineering from Cornell University in 1999 with Co-op experience at Abiomed, Inc., working on total artificial hearts. He then earned his Ph.D. in Biomedical Engineering from the University of Florida, focused on engineering cell-material interactions to prevent and enhance adhesion. This was followed by postdoctoral training at Harvard University, developing new biomaterials and stem cell-based cardiac tissue engineering strategies. Dr. Feinberg has co-authored over 50 peer-reviewed publications, holds over 20 US patents and patent applications, and has received multiple honors including the NSF CAREER Award, the NIH Director’s New Innovator Award, and Fellow of the American Institute for Medical and Biological Engineering. A primary research focus is engineering extracellular matrix (ECM) protein scaffolds using advanced biomanufacturing and 3D bioprinting approaches for multiple applications including cancer models, regenerative scaffolds, skeletal muscle, and cardiac muscle tissue engineering. At FluidForm, he is driving the commercialization of the FRESH 3D bioprinting platform for a wide range of applications in the biopharma, medical device, and regenerative medicine industries.
William is a Ph.D. candidate within the School of Biomedical Engineering at the University of Melbourne. He obtained a Certificate 3 in Business Management and an Honors Degree in Medical Biotechnology from the University of New South Wales where he first entered research focusing on biomaterials, stem cells, and nanofabrication processes for tissue regeneration. Currently, his Ph.D. investigates the use of acoustic micromanipulation and 3D bioprinting as tools to pattern and define the cellular microenvironment. William has held roles as a research assistant and a business development consultant, where he currently serves as a Community and Events Manager for 3D Heals and an Organizing Committee Member for the Australian Bioprinting Workshop.